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CObjective: Viral hepatitis C (HCV) affects 170 million patients world-
wide and 2 million patients in Japan. The objective of the current study
was to examine the burden of HCV in Japan from a patient’s
perspective. Methods: Using data from the 2008 and 2009 Japan Na-
ional Health and Wellness Surveys, patients who reported an HCV
iagnosis (n  306) were compared with a propensity-score–matched
ontrol group (n 306) on measures of quality of life (using the Medical
utcomes Study 12-Item Short Form Survey Instrument version 2),
ork productivity (using the Work Productivity and Activity Impair-
ent questionnaire), and health-care resource use. All analyses ap-
lied sampling weights to project to the population. Results: Prior to
matching, patients with HCV had higher rates of hepatocellular carci-
noma (4.88% vs. 0.02%) and cirrhosis (12.20% vs. 0.11%) than did sub-
jects without HCV. The propensity-matching process eliminated differ-
ences between the two groups on demographics and patient O
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oi:10.1016/j.jval.2011.11.012haracteristics. The postmatching analysis found significantly lower
evels of quality of life for patients with HCV as measured by bodily pain
72.07 vs. 76.28), general health (44.64 vs. 48.61), and mental health
66.50 vs. 70.32) (all Ps  0.05). Furthermore, compared with the
atched group, the HCV group had significantly higher workplace ab-
enteeism (8.59% vs. 4.12%), overall work impairment (26.08% vs.
7.32%), and health-care provider visits in the past 6 months (14.80 vs.
.74). Conclusions: The results of this study suggest that HCV can be a
ubstantial burden on patients in terms of quality of life in both phys-
cal and mental health measures. In addition, HCV can be a significant
ost driver in terms of health-care use and lost productivity.
eywords: hepatitis C, quality of life, resource use, work productivity.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Viral hepatitis C (HCV), a blood-borne communicable disease, af-
fects 170 million patients worldwide [1] and 2 million patients in
Japan [2]. HCV genotype 1b, the most prevalent genotype, spread
uickly in Japan in the 1930s because of the use of contaminated
eedles, both among injectable drug users and among those re-
eiving blood transfusions [3]. The incidence of HCV has since
ecreased, but its sequelae, hepatocellular carcinoma (HCC) in
articular, have become a major public health burden. Japan has
he highest rate of HCC in the industrialized world [4], where it is
the fourth leading cause of death among males and fifth among
females [3]. Evidence suggests that HCV is related to 50% to 76% of
these cases [3–5].
Apart from pathological complications, the presence of HCV
has been associated with decreased health-related quality of
life (HRQOL) and work productivity, and increased resource
use—though most of the research has been conducted in the
United States. Patients with HCV reported significantly lower
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and funded the analysis and writing of this article. Y.Y. and G.J.L..
* Address correspondence to: Marco daCosta DiBonaventura, Kan
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098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.levels of HRQOL relative to healthy controls [6], especially
among the domains of depression, fatigue, vitality, and social
and cognitive function [7–9]. Also, in the United States, esti-
mated direct health-care costs related to HCV amounted to
$2070 per patient per year in 1997 [10] and a median of $6864 per
patient per year during the period 2002 to 2006 [11]. The indirect
costs of work productivity loss have also been shown to be as-
sociated with the presence of HCV. Specifically, absenteeism
(missed work because of illness) and presenteeism (impairment
while at work) have been shown to be higher among patients
with HCV [12] while the overall labor force participation has
been shown to be lower [13,14].
Unlike data from the United States, data on the HCV disease
urden from other parts of the world, particularly Asia, are lim-
ted. Across all member countries, the World Health Organiza-
ion estimates the burden of disease for a variety of conditions
y calculating the number of lives lost because of premature
eath and disability (disease-adjusted life-years) [15]. A total of
60,000 and 229,000 years of healthy lives were lost in Southeast
sia and the Western Pacific, respectively, because of HCV [15].
S) was conducted by Kantar Health. M.D. and J.S.W. are full-time
alth. Bristol-Myers Squibb purchased access to the NHWS data set
ull-time employees of Bristol-Myers Squibb.
ealth, 11 Madison Avenue, 12th Floor, New York, NY 10010, USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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incidence, disease duration, and disease weight), the variety of
assumptions inherent in the calculation, and the scarcity of
country-level (as opposed to region-level) results, the disease-
adjusted life-year comparisons are crude and are difficult to use
to determine the incremental effect of HCV in countries such as
Japan.
Some studies have shown detriments in HRQOL (Short form 36
health survey [SF-36]) among Japanese patients with HCV com-
pared with the general Japanese population (normative SF-36
scores) [16,17]. No study to our knowledge, however, has assessed
comprehensive differences between patients with HCV and a
comparable group without HCV. Direct medical costs in Japan re-
lated to viral hepatitis have been estimated (¥256 billion per year
or approximately $3.2 billion per year) [18], but more evidence is
needed to ascertain the specific costs attributable to the presence
of HCV. Furthermore, we are not aware of any studies published
that have assessed the HCV-related indirect cost (lost productiv-
ity) among the Japanese population.
Because of the unique history and epidemiology of HCV in
Japan, it would not be prudent to extrapolate health outcome
findings from the United States to Japan. Population-level re-
search using Japan data is necessary to fully understand the
societal impact of HCV, including the association of the virus
with HRQOL, work productivity, and resource use. It is also cru-
cial to investigate potential confounding variables that may
contribute to a relationship between HCV status and these out-
comes. As such, the present study attempts to determine the
incremental effect of HCV on HRQOL, work productivity loss,
and resource utilization by using a large, nationally representa-
tive Japan database. The study was designed to control for the
potential confounding factors across the study groups by using
Table 1 – Representativeness of the 2008 Japan NHWS data
NHWS
sample size
Gender
Male 10,994
Female 9,006
Age (y)
18–39 6,200
40–64 8,400
65 5,400
Annual household income
¥3,000,000 ($36,000) 3,057
¥3,000,000–¥4,999,999 ($36,000–$60,000) 5,279
¥5,000,000–¥7,999,999 ($60,000–$96,000) 5,244
¥ 8,000,000 ($96,000) 4,641
Region
Hokkaido 1,005
Tohoku 957
Kanto 8,332
Chubu 2,767
Kinki 4,022
Chugoku 952
Shikoku 461
Kyushu 1,391
Okinawa 113
NHWS, The National Health and Wellness Survey.
* Data on the Japan population was obtained from the Japan Mini
International Database (http://www.census.gov/ipc/www/idb/).a propensity-score matching methodology. These results will rhelp provide a robust estimate of the association between HCV
and health outcomes in Japan.
Methods
Data source
The current study used data from the 2008 (N 20,000) and 2009
(N  20,573) Japan National Health and Wellness Surveys
(NHWS; Kantar Health, New York, NY), an annual, cross-sec-
tional study of adults aged 18 years or older. The NHWS includes
epidemiological data, treatment information, information on
health risk behaviors, and health-related outcome data. Poten-
tial respondents to the NHWS are recruited through an existing
Web-based consumer panel. The consumer panel recruits its
panel members through opt-in emails, coregistration with
panel partners, e-newsletter campaigns, banner placements,
and both internal and external affiliate networks. All panelists
must explicitly agree to be a panel member, register with the
panel through a unique email address, and complete an in-
depth demographic registration profile. All subjects provided
informed consent, and the study was approved by Essex Insti-
tutional Review Board (Lebanon, NJ).
Using a stratified random sample framework (with quotas
based on gender and age), the demographic composition of the
2008 and 2009 Japan NHWS samples is comparable to that of the
Japanese adult population (see Table 1). Because the NHWS uses
random sampling with replacement each year, a subset of 2008
respondents also completed the survey in 2009. In these instances,
only 2009 data were included so as to avoid nonunique responses.
Of the total sample (N  37,683), 312 patients reported ever expe-
.
NHWS 2008
Japan
population* (%)
Raw data (not
weighted) (%)
Data
(weighted) (%)
55.0 48.3 48.3
45.0 51.7 51.7
31.0 34.1 34.1
42.0 40.0 40.0
27.0 25.9 25.9
16.8 17.6 21.1
29.0 28.7 29.0
28.8 28.6 27.5
25.5 25.1 22.4
5.0 5.2 4.4
4.8 4.8 7.6
41.7 41.5 32.4
13.8 13.9 17.0
20.1 20.0 17.9
4.8 4.7 6.0
2.3 2.4 3.2
7.0 7.0 10.5
0.6 0.6 1.1
f Internal Affairs & Communications via the US Census Bureau’sbase
stry oiencing HCV and 37,371 respondents reported otherwise.
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Health-related quality of life
The Japanese Medical Outcomes Study 12-Item Short Form Survey
Instrument version 2 is a multipurpose, generic HRQOL instru-
ment comprising of 12 questions (Quality Metric, Lincoln, RI). It is
an updated version of the Japanese Medical Outcomes Study 12-
Item Short Form Survey Instrument, whose questions were se-
lected from the SF-36 health survey [19,20] and translated and
alidated for use in the Japanese population [21,22]. The instru-
ent is designed to report on eight health domains—physical
unctioning, physical role limitations, bodily pain, general health,
itality, social functioning, emotional role limitations, and mental
ealth—two summary scores (mental component summary [MCS]
nd physical component summary [PCS]), and health state utili-
ies (six-dimensional health state short form [derived from SF-36]).
or the purpose of the present analysis, the normed versions of the
CS and MCS summary scores were used. This was achieved by
ransforming the raw scores for the items to a mean of 50 and an
D of 10 for the population. The six-dimensional health state short
orm (derived from SF-36)is a preference-based single index mea-
ure for health using general population values [23,24]. The six-
imensional health state short form (derived from SF-36) index
as interval-scoring properties and yields summary scores on a
heoretical 0 to 1 scale.
Health-care utilization
Patients were also asked about their use of health-care resources.
Resource utilization was considered in terms of the number of
visits in the last 6 months to health-care providers (practitioner/
family practitioners, internists, and dentists as well as more spe-
cialized physicians), the emergency room (ER), and the hospital for
the patient’s own medical condition.
Work productivity and activity impairment
The Work Productivity and Activity Impairment questionnaire
was used to measure the impact of health on employment-related
activities. It is a six-item validated instrument that consists of four
metrics: absenteeism (the percentage of work time missed be-
cause of one’s health in the past 7 days), presenteeism (the per-
centage of impairment experienced because of one’s health while
at work in the past 7 days), overall work productivity loss (an over-
all impairment estimate that is a combination of absenteeism and
presenteeism), and activity impairment (the percentage of impair-
ment in daily activities because of one’s health in the past 7 days).
The validity of the instrument has been established in a number of
disease states (e.g., irritable bowel syndrome, asthma, and derma-
titis) [25,26].
Absenteeism was calculated by dividing the number of work
hours a patient missed in the past week because of his or her
health by the total number of hours a patient could have worked
(the number of hours he or she did work plus the number of hours
missed because of his or her health) and converting this propor-
tion into a percentage. Presenteeism was measured by a patient’s
rating of his or her level of impairment experienced while at work
in the past 7 days (from 0 to 10, with higher numbers indicating
greater impairment), which was then multiplied by 10 to create a
percentage, with a range from 0% to 100%. Overall work impair-
ment was measured by combining absenteeism and presenteeism
to determine the total percentage of lost work time. Activity im-
pairment was measured by a patient’s rating of the level of impair-
ment experienced in daily activities in the past 7 days (from 0 to 10,
with higher numbers indicating greater impairment), which was
then multiplied by 10 to create a percentage, with a range from 0%
to 100%.Confounding variables
Based on previous research [6], it was anticipated that patients
with HCV would differ in several meaningful ways from those
without HCV. Many of these variables may also be related to the
health outcomes of interest. As such, a variety of demographic,
health history, and comorbidity variables were included in the
analyses to address potential alternative explanations. Specifi-
cally, demographic variables included age, gender, marital status
(married/living with partner vs. all else), educational attainment
(university degree vs. all else), employment status (currently em-
ployed vs. not employed), insurance coverage (national health in-
surance, social health insurance, late-stage elderly insurance,
other insurance, unknown insurance), and annual household in-
come in Japanese yen (¥3,000,000, ¥3,000,000–¥4,999,999,
¥5,000,000–¥7,999,999, ¥8,000,000, decline to answer; when con-
verted to the US dollar, these categories correspond to $36,000,
$36,000–$60,000, $60,000–$96,000, $96,000).
Health history variables included tobacco smoking (current
smoker vs. nonsmoker), alcohol consumption (drink alcohol vs. all
else), body mass index, and physical exercise (exercise once or
more per month for 20 minutes vs. all else). For the assessment of
comorbidity status, the Charlson comorbidity index (CCI) was cal-
culated for each respondent by weighting the presence of each
comorbidity and summing the result [27]. The CCI includes the
following comorbidities: myocardial infarction, congestive heart
failure, peripheral vascular disease, cerebrovascular disease, de-
mentia, chronic pulmonary disease, connective tissue disease, ul-
cer disease, mild liver disease, diabetes, hemiplegia, moderate or
severe renal disease, diabetes with end organ damage, any tumor,
leukemia, lymphoma, moderate to severe liver disease, and met-
astatic solid tumor [27]. Separately, the presence of hepatitis B,
HIV/AIDS, HCC, and cirrhosis was also assessed. Finally, self-re-
ported anxiety and depression, which have been known to be sig-
nificantly associated with the underlying HCV and its treatment,
were also measured for all patients.
Statistical analysis
As shown in previous research, patients with HCV had significantly
different characteristics compared with those without HCV, includ-
ing higher age, more physical comorbidities, and higher levels of anx-
iety and depression. To more appropriately address the potential
issue of selection bias, a propensity score matching methodology
was implemented. Specifically, year of the data (2008 vs. 2009), age,
gender, education, household income, health insurance, employ-
ment status, presence of self-reported anxiety, depression, hepatitis
B, and HIV/AIDS, comorbidity burden (using the CCI, excluding the
comorbidities noted previously), smoking, exercise, alcohol use, and
body mass index were included in a logistic regression to predict
group assignment (HCV group vs. unmatched control group). Be-
cause HCC and cirrhosis are endogenous to HCV, we did not include
them as part of the matching process.
Each patient with HCV was matched with a control whose pro-
pensity score was nearest by using an SAS macro (greedy match-
ing algorithm). The greedy matching algorithm is one of the most
widely used algorithms in propensity score matching analysis and
allows for each case to be matched with the most suitable control
available at that point in the matching process [28]. This is done by
performing up to seven passes to find one matched control for
each case. First, the algorithm searches for a control with a pro-
pensity score within 0.0000001 of a case’s propensity score value. If
none is found, then the algorithm searches for a control within
0.000001 and continues searching for a suitable control with de-
creasingly restrictive criteria (0.00001, 0.0001, 0.001, and 0.01) until
a control is found [28].
Differences between the HCV group and the matched control
group were analyzed by using chi-square tests for categorical vari-
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postmatch (i.e., controlling for any remaining differences after the
matching process) were conducted by using multiple regressions
for quality of life and generalized linear models (specifying a neg-
ative binomial distribution) for work productivity and health-care
resource use. All analyses were conducted by using SAS v9.1 (SAS,
Inc., Cary, NC). Sampling weights were applied to all analyses.
Statistical significance was set a priori to a two-tailed P  0.05.
Results
Prior to matching, 44.38% of patients with HCV were female and
the mean age was 60.14 (SD 12.56) (see Table 2). Patients with HCV
had higher rates of HCC (4.88% vs. 0.02%; P  0.05) and cirrhosis
(12.20% vs. 0.11%; P  0.05) compared with non-HCV patients, as
would be expected given the history of HCV in Japan.
In all domains of the Medical Outcomes Study 12-Item Short
Form Survey Instrument version 2 except for mental health and
vitality, mean HRQOL scores were significantly lower for pa-
tients with HCV compared with unmatched controls. The mean
PCS score was significantly lower for patients with HCV com-
Table 2 – Demographic and health risk behavior difference
diagnosed with HCV.
Variable Unmatched control group (n  3
n Weighted n Weighted %
2009 study participant 20,409 57,732,215 53.97
Female 16,513 54,778,253 51.21
Married 25,864 70,671,081 66.07
College educated 19,033 53,874,717 50.37
Employed 21,678 61,645,927 57.63
Possess national health
insurance
16,865 48,141,358 45.01
Possess social health
insurance
18,180 52,268,246 48.86
Possess late-stage
elderly insurance
684 1,736,734 1.62
Possess other insurance 764 2,150,265 2.01
Unknown insurance 878 2,670,937 2.50
Annual household
income
¥3,000,000
($36,000)
5,929 17,643,449 16.49
¥3,000,000–¥4,999,999
($36,000–$60,000)
9,804 27,606,324 25.81
¥5,000,000–¥7,999,999
($60,000–$96,000)
9,671 27,381,323 25.60
¥8,000,000
($96,000)
8,538 24,036,840 22.47
Decline to answer 3,429 10,299,604 9.63
Currently smoke 9,512 26,586,186 24.85
Use alcohol 28,040 78,139,050 73.05
Currently exercise 18,185 51,121,006 47.79
Presence of anxiety 1,766 5,228,942 4.89
Presence of depression 1,708 5,066,077 4.74
Presence of HBV 288 741,583 0.69
Presence of HIV/AIDS 25 74,890 0.07
Mean SD SE
Age (y) 48.15 16.04 0.08
BMI 22.31 3.48 0.02
CCI 0.31 0.73 0.00
BMI, body mass index; CCI, Charlson comorbidity index; HBV, viral hpared with their unmatched peers (45.79 vs. 50.44; P  0.0001), awhile the MCS score was not. Furthermore, patients with HCV
reported significantly higher mean health-care provider visits
(16.68 vs. 5.68), ER visits (0.73 vs. 0.12), and hospitalizations (2.93
vs. 0.55) in the last 6 months compared with unmatched con-
trols (all Ps  0.0001).
Only those respondents who reported being employed full-
time, employed part-time, or self-employed provided data for ab-
senteeism, presenteeism, and overall work impairment. Among
these respondents, mean levels of absenteeism (percentage of
time missed from work) were significantly higher for patients with
HCV (8.91% vs. 3.06%; P 0.0001), as was presenteeism (percentage
f impairment while at work) (22.06% vs. 16.15%; P 0.01). Among
he entire sample, activity impairment (percentage of impairment
n daily activities) was also found to be significantly higher for
atients with HCV compared with unmatched controls (25.94% vs.
8.57%; P  0.0001).
After propensity matching, the two groups were balanced on
ear of the data (2008 vs. 2009), age, gender, education, household
ncome, health insurance, employment status, and presence of
elf-reported anxiety, depression, hepatitis B, and HIV/AIDS
Table 3). Six patients with HCV (1.92%) were not assigned a match
tween those in Japan diagnosed with HCV and those not
) HCV group (n  312)
PE n Weighted n Weighted % SE
.27% 164 422,363 52.35 3.16% 0.6095
.27% 91 358,050 44.38 3.28% 0.0310
.26% 247 594,575 73.70 3.00% 0.0106
.27% 145 378,590 46.93 3.17% 0.2803
.27% 139 377,740 46.82 3.15% 0.0010
.27% 184 463,469 57.45 3.12% 0.0001
.27% 96 256,988 31.85 2.88% 0.0001
.08% 19 54,545 6.76 1.79% 0.0052
.08% 7 17,869 2.21 0.84% 0.8083
.09% 6 13,884 1.72 0.73% 0.2945
.21% 56 139,426 17.28 2.40% 0.7434
.24% 102 261,908 32.46 2.99% 0.0282
.24% 68 160,119 19.85 2.4% 0.0198
.22% 69 201,471 24.97 2.81% 0.3765
.17% 17 43,832 5.43 1.44% 0.0045
.23% 81 211,002 26.15 2.7% 0.6315
.25% 204 512,833 63.57 3.12% 0.0034
.27% 178 436,636 54.12 3.17% 0.0473
.12% 20 53,997 6.69 1.48% 0.2243
.11% 20 56,939 7.06 1.53% 0.1319
.04% 20 61,505 7.62 1.78% 0.0002
.01% 7 20,558 2.55 0.95% 0.0102
Mean SD SE P
60.14 12.56 0.75 0.0001
22.23 3.21 0.19 0.6928
2.18 3.42 0.20 0.0001
tis B; HCV, viral hepatitis C; SE, standard error; P, p-value.s be
7,371
S
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controls. Despite successfully matching patients with HCV with
controls on the above variables, patients with HCV still reported a
significantly higher mean CCI (1.68 vs. 1.48; P  0.05).
Compared with their matched peers, all HRQOL, work productiv-
ity loss, and health-care resource use outcomes were worse for pa-
tients with HCV, though not always significantly so (see Table 4).
Patients with HCV reported significantly lower means for MCS scores
(46.71 vs. 48.12; P 0.05) and for the domains of bodily pain (72.07 vs.
6.28), general health (44.64 vs. 48.61), and mental health (66.50 vs.
0.32) (all Ps  0.05). No other quality-of-life summary scores or do-
ains were significantly different between the groups.
Similarly, all productivity loss measures were higher for patients
ith HCV. However, only the percentage of absenteeism (8.59% vs.
.12%; P 0.05) and overall work impairment (26.08% vs. 17.32%; P
.05) were significantly greater when compared with the matched
roup. All resource use variables were also higher among patients
ith HCV, though only the difference in health-care provider visits
as statistically significant (14.8 vs. 9.74; P 0.0001).
Because of the imbalance in comorbidity burden, additional
nalyses were rerun controlling for CCI. The results remained gen-
Table 3 – Demographic and health risk behavior difference
propensity-score matched controls.
Matched control group (n  30
n Weighted n Weighted %
2009 study participant 157 398,943 51.63
Female 86 346,683 44.87
Married 248 566,408 73.30
College educated 126 314,148 40.66
Employed 129 326,622 42.27
Possess national health
insurance
194 479,753 62.09
Possess social health
insurance
79 214,896 27.81
Possess late-stage
elderly insurance
22 48,385 6.26
Possess other insurance 10 26,237 3.40
Unknown insurance 1 3,419 0.44
Annual household
income
¥3,000,000 ($36,000) 60 169,867 21.98
¥3,000,000–¥4,999,999
($36,000–$60,000)
89 219,719 28.44
¥5,000,000–¥7,999,999
($60,000–$96,000)
70 161,563 20.91
¥8,000,000
($96,000)
73 180,508 23.36
Decline to Answer 14 41,034 5.31
Currently smoke 73 182,839 23.66
Use alcohol 182 423,404 54.80
Currently exercise 174 408,942 52.92
Presence of anxiety 7 22,429 2.90
Presence of depression 8 20,741 2.68
Presence of HBV 20 51,816 6.71
Presence of HIV/AIDS 0 0 0.00
Presence of HCC 0 0 0.00
Mean SD SE
Age 62.60 11.29 0.69
BMI 22.32 3.37 0.20
CCI 1.48 1.17 0.07
BMI, body mass index; CCI, Charlson comorbidity index; HBV, vira
standard error; P, p-value.rally consistent. Patients with HCV reported significantly lowerevels of MCS (adjusted means  46.77 vs. 48.63; P  0.05), general
ealth (adjusted means  44.35 vs. 48.43; P  0.05), and mental
ealth (adjusted means  66.65 vs. 71.26; P  0.05). Bodily pain
ifferences were no longer significant once accounting for the
reater comorbidity burden of the HCV group. Patients with HCV
eported marginally higher absenteeism (adjusted means 8.35%
s. 3.74%; P  0.06) and marginally higher presenteeism (adjusted
eans  20.01% vs. 14.96%; P  0.09) than did matched controls.
owever, patients with HCV did report significantly higher overall
ork impairment (adjusted means  25.43% vs. 16.35%; P  0.05),
R visits (adjusted means  0.61 vs. 0.18; P  0.05), and physician
isits (adjusted means 14.56 vs. 9.87; P 0.05) than did matched
ontrols. No significant differences were observed on activity im-
airment or hospitalizations.
Discussion and Conclusions
The results demonstrate a significant impact of HCV on a range of
health outcomes, including HRQOL domains, work productivity
loss, and health-care resource use. These effects were observed
tween those in Japan diagnosed with HCV and
HCV group (n  306)
PE n Weighted n Weighted % SE
23% 162 416,513 52.77 3.20% 0.8016
35% 86 343,755 43.55 3.34% 0.7814
16% 243 583,191 73.89 3.04% 0.8933
17% 142 369,682 46.84 3.21% 0.1713
15% 134 362,885 45.98 3.19% 0.4088
12% 178 445,969 56.51 3.17% 0.2096
86% 96 256,988 32.56 2.93% 0.2462
58% 19 54,545 6.91 1.83% 0.7884
15% 7 17,869 2.26 0.86% 0.4305
44% 6 13,884 1.76 0.75% 0.1301
85% 56 139,426 17.67 2.45% 0.2521
93% 102 261,908 33.18 3.04% 0.2617
54% 66 154,415 19.56 2.42% 0.7019
62% 65 189,674 24.03 2.82% 0.8616
52% 17 43,832 5.55 1.48% 0.9087
68% 76 196,561 24.90 2.69% 0.7440
25% 198 495,333 62.76 3.17% 0.0808
25% 172 419,136 53.11 3.21% 0.9684
18% 14 36,498 4.62 1.24% 0.3154
97% 14 39,440 5.00 1.31% 0.1566
58% 15 46,703 5.92 1.65% 0.7299
– 1 3058 0.39 0.39% –
– 7 15,875 3.81 1.77% –
Mean SD SE P
60.64 12.08 0.73 0.0505
22.23 3.19 0.19 0.7554
1.68 1.14 0.07 0.0377
atitis B; HCC, hepatocellular carcinoma; HCV, viral hepatitis C; SE,s be
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status. Although only some differences between groups were sta-
tistically significant (namely, MCS, general health, mental health,
overall work productivity, ER visits, and physician visits), all out-
comes were worse among patients with HCV, highlighting the per-
vasive consequences of the virus.
Because this is the first study of its kind that has used a pro-
pensity score analysis on nationally representative data from Ja-
pan, comparisons between the current study and prior research
are difficult. Although previous studies have documented a lower
level of HRQOL among patients with HCV compared with controls,
they were based on tertiary care samples, which may not be rep-
resentative of patients with HCV in the Japanese population
[16,17]. Furthermore, these studies failed to appreciate the poten-
tially confounding effects of demographic, health risk behavior,
and comorbidity profiles in patients with HCV, which may have
overestimated the difference between subjects with HCV and
those without [16,17].
Aside from documenting the overall burden of HCV, the cur-
rent study adds to the evidence of the cost consequences of the
virus in Japan [18]. Although cost analyses were not part of this
study, presumably patients with HCV would have greater direct
costs because of the greater number of physician visits (over 50%
more) and ER visits (over 200% more) relative to matched controls.
It is important to note that medication information was not avail-
able and should be examined in future research to more fully cap-
ture the resource use and direct cost burden of HCV.
Patients with HCV would also have greater indirect costs be-
cause of greater rates of overall work impairment (primarily
caused by greater absenteeism rates). The additional 8.76% work
time missed in patients with HCV relative to matched controls
would extrapolate to 22 extra workdays missed per patient per
Table 4 – Health outcome differences between those in Jap
controls.
Matched control group (n
n Weighted n Weighted
Visited traditional HCP 277 691,159 89.45
Visited nontraditional HCP 64 175,764 22.75
Mean SD
SF-12v2:
Mental component summary 48.12 9.18
Physical component
summary
46.64 7.78
Bodily pain 76.28 23.32
General health 48.61 21.04
Mental health 70.32 18.86
Physical functioning 81.26 24.75
Role emotional 77.77 21.57
Role physical 73.95 22.53
Social functioning 76.92 24.79
Vitality 53.81 24.45
Health state utilties 0.74 0.13
Absenteeism (%) 4.12 13.20
Presenteeism (%) 15.48 21.59
Overall work impairment (%) 17.32 23.89
Overall activity impairment (%) 23.80 24.72
ER visits in last 6 mo 0.19 1.02
Hospitalizations in last 6 mo 1.97 9.56
Health-care visits in last 6 mo 9.74 9.27
ER, emergency room; HCP, health-care practitioner; HCV, viral hepat
Form Survey Instrument version 2; P, p-value.year, assuming 250 working days per year. It is also worth empha-sizing that because of the propensity-matching methodology,
these differences could be assumed to be an independent effect of
HCV, beyond any effects of concomitant characteristics of these
patients such as increased anxiety, depression, and other comor-
bidities. Prior studies have neglected to account for many of these
differences, which may have resulted in overestimates of the ef-
fect of HCV.
The results of this study are also consistent with the work con-
ducted in the United States [6,12–14] and highlight the burden of
this condition. Of course, given the uniqueness of the epidemiol-
ogy of the virus in Japan, it is important to investigate HCV specif-
ically within Japan rather than relying on estimates from other
geographies. Because the peak period of infection was earlier than
the United States, for instance, the average age of our HCV sample
(60 years) is 10 years older than that of patients with HCV in the
United States [6]. Further research, particularly surrounding the
cost consequences, may be necessary, but our study, which explic-
itly controlled for various confounding variables, clearly demon-
strates a substantive impact of HCV on a variety of health out-
comes among the population in Japan.
The limitations of the current study should be noted. Al-
though alternative explanations have been included (demo-
graphics, health history, comorbidities, etc.) through the use of
propensity matching, it is possible that other unmeasured vari-
ables might explain the relationship between the presence of
HCV and health outcomes. Because of the self-reported nature,
recall bias may have introduced additional error into the ob-
served associations. It should also be emphasized that although
the NHWS is demographically representative of the overall Jap-
anese population, the sample in the current study of patients
with HCV may differ in meaningful ways from the Japanese HCV
population, which could affect the size and direction of the re-
iagnosed with HCV and propensity-score matched
6) HCV group (n  306) P
SE n Weighted n Weighted % SE
2.07% 277 716,660 90.80 1.72% 0.6162
2.78% 77 206,449 26.16 2.86% 0.3933
E Mean SD SE P
.56 46.71 9.50 0.57 0.0791
.47 45.96 7.71 0.46 0.3029
.42 72.07 24.92 1.50 0.0419
.28 44.64 22.83 1.38 0.0352
.15 66.50 20.45 1.23 0.0238
.51 81.11 25.27 1.52 0.9415
.31 76.06 23.22 1.40 0.3717
.37 72.19 23.56 1.42 0.3732
.51 74.63 24.62 1.48 0.2810
.49 51.62 25.65 1.54 0.3074
.01 0.72 0.13 0.01 0.1429
.31 8.59 19.28 1.81 0.0492
.05 20.62 24.08 2.19 0.089
.36 26.08 29.12 2.73 0.0167
.50 25.37 26.62 1.60 0.474
.06 0.64 4.65 0.28 0.1176
.58 2.77 12.89 0.78 0.4135
.56 14.80 15.18 0.91 0.0001
SE, standard error; SF-12v2, Medical Outcomes Study 12-Item Shortan d
 30
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S71V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 6 5 – S 7 1Based on our analyses, there were many differences between
patients with HCV and unmatched controls (Table 2), all of which
(CCI aside) were eliminated in our propensity score matching pro-
cess (Table 3). As such, our data suggest that without proper
matching, the comparison between patients with and without
HCV does not provide the accurate assessment of the impact of
HCV on HRQOL, resource use, and work productivity impairment.
Furthermore, when appropriate matched control subjects were
used, HRQOL, resource use, and work productivity were still sig-
nificantly different between patients with HCV and controls.
Of course, the use of propensity scoring does not allow a com-
parison of the impact of HCV in relation to the impact of demo-
graphics, health risk factors, and other comorbidities on these out-
comes. A regression modeling framework or instrumental variable
approach may allow this comparison, which is worth further anal-
ysis in future research. In sum, the results of this study suggest
that HCV can be a substantial burden on patients in terms of qual-
ity of life at both physical and mental health measures. In addi-
tion, HCV can be a significant cost driver in terms of health-care
use and lost productivity.
Source of financial support: Bristol-Myers Squibb purchased
access to the National Health and Wellness Survey and funded the
analysis for this project.
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